Movement disorders : official journal of the Movement Disorder Society · 2026
Diagnostic Value of Glycocalyx Shedding in Blood for Differentiating between Parkinson's Disease and Multiple System Atrophy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Folke Jonas, DellaValle Brian, Jørgensen Mathias Lindh, Mogensen Phillip Bredahl, Hempel Casper, Rungby Jørgen, Hejl Anne-Mette, Løkkegaard Annemette, Salvesen Lisette, Bech Sara, Møller Mette, Danielsen Erik Hvid, Blaabjerg Morten, Bode Matthias, Brudek Tomasz, Aznar Susana
Аннотация
BACKGROUND: Blood-brain barrier disruption is increasingly recognized in synucleinopathies, but the role of the endothelial glycocalyx (GLX) in Parkinson's disease (PD) and multiple system atrophy (MSA) remains unclear.
OBJECTIVES: The aim was to determine whether plasma GLX markers differ between PD, MSA, and healthy controls (HC), relate to clinical measures, and support differential diagnosis.
METHODS: Nine GLX analytes were quantified in plasma from 38 PD, 24 MSA, and 46 HC. Group differences were tested with multilinear regression including age and sex; associations with disease duration, Hoehn and Yahr stage, and Montreal Cognitive Assessment score were examined; gradient boosting classifiers plus Shapley Additive Explanations and univariate receiver operating characteristic (ROC) analyses evaluated discriminative performance.
RESULTS: PD showed reduced biglycan and cluster of differentiation 44 (CD44), whereas MSA showed increased chondroitin sulfate and reduced perlecan and CD44 versus comparators. Several GLX markers correlated with duration and cognition. Multianalyte GLX signatures classified groups with ROC area under curve, 0.79 to 0.88.
CONCLUSIONS: In this exploratory cohort, distinct GLX signatures reflect disease-specific neurovascular dysfunction and may aid stratification and monitoring. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
OBJECTIVES: The aim was to determine whether plasma GLX markers differ between PD, MSA, and healthy controls (HC), relate to clinical measures, and support differential diagnosis.
METHODS: Nine GLX analytes were quantified in plasma from 38 PD, 24 MSA, and 46 HC. Group differences were tested with multilinear regression including age and sex; associations with disease duration, Hoehn and Yahr stage, and Montreal Cognitive Assessment score were examined; gradient boosting classifiers plus Shapley Additive Explanations and univariate receiver operating characteristic (ROC) analyses evaluated discriminative performance.
RESULTS: PD showed reduced biglycan and cluster of differentiation 44 (CD44), whereas MSA showed increased chondroitin sulfate and reduced perlecan and CD44 versus comparators. Several GLX markers correlated with duration and cognition. Multianalyte GLX signatures classified groups with ROC area under curve, 0.79 to 0.88.
CONCLUSIONS: In this exploratory cohort, distinct GLX signatures reflect disease-specific neurovascular dysfunction and may aid stratification and monitoring. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.